<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482222</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000549541</org_study_id>
    <secondary_id>USCTU-4351</secondary_id>
    <secondary_id>USCTU-EPOC</secondary_id>
    <secondary_id>EUDRACT-2006-003121-82</secondary_id>
    <secondary_id>ISRCTN22944367</secondary_id>
    <secondary_id>EU-20732</secondary_id>
    <nct_id>NCT00482222</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer</brief_title>
  <official_title>A Prospective Randomised Open Label Trial of Oxaliplatin/Fluoropyrimidine Versus Oxaliplatin/Fluoropyrimidine Plus Cetuximab Pre and Post Operatively in Patients With Resectable Colorectal Liver Metastasis Requiring Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and
      capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block
      tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
      Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving
      combination chemotherapy together with monoclonal antibodies before surgery may make the
      tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these
      treatments after surgery may kill any tumor cells that remain after surgery. It is not yet
      known whether combination chemotherapy is more effective with or without cetuximab in
      treating liver metastases caused by colorectal cancer.

      PURPOSE: This randomized phase III trial is studying combination chemotherapy to compare how
      well it works when given with or without cetuximab before and after surgery in treating
      patients with resectable liver metastases caused by colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare progression-free survival of patients with resectable colorectal liver
           metastases treated with neoadjuvant and adjuvant combination chemotherapy with vs
           without cetuximab.

      Secondary

        -  Compare the overall survival of patients treated with these regimens.

        -  Compare the quality of life of patients treated with these regimens.

        -  Compare the cost effectiveness of these regimens in these patients.

      OUTLINE: This is a prospective, randomized, multicenter, open-label study. Patients are
      stratified according to participating center and assigned chemotherapy regimen. Patients are
      randomized to 1 of 2 treatment arms.

        -  Neoadjuvant therapy:

             -  Arm I: Patients receive 1 of the following chemotherapy regimens:

                  -  OxMdG: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV
                     over 2 hours on day 1. Patients also receive fluorouracil IV continuously over
                     46 hours beginning on day 1. Treatment repeats every 2 weeks for up to 6
                     courses in the absence of disease progression or unacceptable toxicity.

                  -  CAPOX: Patients receive oxaliplatin IV over 2 hours on day 1 and oral
                     capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for up
                     to 4 courses in the absence of disease progression or unacceptable toxicity.

             -  Arm II: Patients receive 1 of the following regimens:

                  -  OxMdG + cetuximab: Patients receive cetuximab IV over 1-2 hours on day 1 and
                     OxMdG chemotherapy as in arm I. Treatment repeats every 2 weeks for up to 6
                     courses in the absence of disease progression or unacceptable toxicity.

                  -  CAPOX + cetuximab: Patients receive cetuximab IV over 1-2 hours on days 1, 8,
                     and 15 and CAPOX chemotherapy as in arm I. Treatment repeats every 3 weeks for
                     up to 4 courses in the absence of disease progression or unacceptable
                     toxicity.

        -  Surgery: Beginning 2-6 weeks after completion of chemotherapy, patients in both arms
           undergo liver resection.

        -  Adjuvant therapy: Beginning 4-8 weeks after completion of surgery, patients receive
           treatment (OxMdG or CAPOX with or without cetuximab) as in arm I or II of neoadjuvant
           therapy.

             -  Arm I: Treatment with OxMdG repeats every 2 weeks for up to 6 courses and treatment
                with CAPOX repeats every 3 weeks for up to 4 courses in the absence of disease
                progression or unacceptable toxicity.

             -  Arm II: Treatment with OxMdG + cetuximab repeats every 2 weeks for up to 6 courses
                and treatment with CAPOX + cetuximab repeats every 3 weeks for up to 4 courses in
                the absence of disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, every 12 weeks during chemotherapy, at completion of
      study treatment, every 3 months for 1 year, and then every 6 months thereafter.

      Cost per life year and per quality-adjusted life year is assessed at baseline, every 12 weeks
      during treatment, and then at 3, 5, and 10 years.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for 3 years.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate before surgery as assessed by RECIST criteria</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological resection status</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by the EQ-5D, EORTC QLQ-C30, and EORTC QLQ-LMC21</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study of socioeconomic and demographic variables</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>OxMdG / IrMdG chemotherapy</arm_group_label>
    <arm_group_label>OxMdG / IrMdG chemotherapy with cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically* or radiologically confirmed primary adenocarcinoma of the colon or
             rectum

               -  Advanced and/or metastatic disease NOTE: *Liver metastases should not be biopsied

          -  Must have potentially resectable liver metastases present, as defined by any of the
             following:

               -  Metachronous metastases AND complete resection of the primary tumor without gross
                  or microscopic evidence of residual disease (R0)

               -  Synchronous metastases AND R0 resection of the primary tumor &gt; 1 month before
                  study entry

               -  Synchronous metastases with sufficient evidence (e.g., by CT scan or diagnostic
                  laparoscopy) that both the primary tumor and the liver metastases can be
                  completely resected during the same procedure and resection of primary tumor can
                  be delayed for 3-4 months

               -  Suboptimally resectable disease (i.e., potentially resectable disease with
                  compromise of the resection margins)

          -  No detectable extrahepatic tumor that cannot be completely resected

          -  Unidimensionally measurable disease

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-2

          -  WBC ≥ 4,000/mm³

          -  ANC ≥ 1,500/mm³

          -  Platelet count &gt; 150,000/mm³

          -  Bilirubin ≤ 1.25 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 5 times ULN

          -  AST or ALT ≤ 3 times ULN

          -  Creatinine clearance &gt; 50 mL/min OR glomerular filtration rate &gt; 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 3 months after
             completion of study treatment

          -  No psychiatric or neurological condition that would preclude study compliance

          -  No partial or complete bowel obstruction

          -  No preexisting neuropathy &gt; grade 1

          -  No other prior or concurrent malignant disease that, in the opinion of the
             investigator, would preclude study treatment

          -  No concurrent severe uncontrolled medical illness (including poorly-controlled angina
             or myocardial infarction within the past 3 months) that would preclude study treatment

          -  No known hypersensitivity reaction to any of the components of the study drugs

        PRIOR CONCURRENT THERAPY:

          -  No prior systemic chemotherapy for metastatic disease

          -  More than 6 months since prior adjuvant chemotherapy comprising fluorouracil,
             leucovorin calcium, capecitabine, or irinotecan hydrochloride

          -  More than 1 month since prior rectal chemoradiotherapy comprising fluorouracil and
             leucovorin calcium

          -  No concurrent contraindicated medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John N. Primrose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louisa Little</last_name>
    <phone>02380795154</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Basildon University Hospital</name>
      <address>
        <city>Basildon</city>
        <state>England</state>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Leonard, MD</last_name>
      <phone>44-1702-435-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Rees, MD</last_name>
      <phone>44-125-631-4793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hickish, MD</last_name>
      <phone>44-1202-303-626</phone>
      <email>tamas.hickish@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pippa Corrie, PhD, FRCP</last_name>
      <phone>44-1223-274-401</phone>
      <email>pippa.corrie@addenbrookes.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharadah Essapen, MD</last_name>
      <phone>44-1483-571-122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graeme J. Poston, MD</last_name>
      <phone>44-151-525-5980</phone>
      <email>graeme.poston@aintree.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ghaneh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Slater, MD</last_name>
      <phone>44-20-7601-8391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Mayer, MD</last_name>
      <phone>44-207-794-0500</phone>
      <email>a.mayer@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cunningham, MD</last_name>
      <phone>44-20-8661-3156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles P. Lowdell, MD, BSc, MBBS, FRCP, FRCR</last_name>
      <phone>44-208-383-0576</phone>
      <email>charles.lowdell@imperial.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smith, MD</last_name>
      <phone>44-151-334-1155</phone>
      <email>david.smith@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Newport</city>
        <state>England</state>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Baughan, MD</last_name>
      <phone>44-1983-524-081</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Hornbuckle, MD</last_name>
      <phone>44-115-969-1169 ext. 47599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hickish, MD</last_name>
      <phone>44-1202-442-532</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>England</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim J. Iveson, MD</last_name>
      <phone>44-1722-336-262 ext. 4688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John N. Primrose, MD</last_name>
      <phone>44-23-8079-6144</phone>
      <email>j.n.primrose@soton.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cunningham, MD</last_name>
      <phone>44-20-8661-3279</phone>
      <email>david.cunningham@rmh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Leonard, MD</last_name>
      <phone>44-1702-435-555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Webb, MD</last_name>
      <phone>44-1903-205-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Maughan, MD</last_name>
      <phone>44-2920-316-904</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Maughan, MD</last_name>
      <phone>44-2920-316-904</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

